Last €33.96 EUR
Change Today +0.175 / 0.52%
Volume 0.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 7:17 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

James M. Frates

Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer, Alkermes plc
AgeTotal Calculated CompensationThis person is connected to 16 board members in 1 different organizations across 2 different industries.

See Board Relationships
47$1,831,191
As of Fiscal Year 2013

Background*

Mr. James M. Frates, also known as Jim, has been the Chief Financial Officer and Treasurer of Alkermes Inc., and Alkermes Plc since June 1998 and serves as its Principal Accounting Officer. Mr. Frates has been a Senior Vice President of Alkermes, Inc. since May 22, 2007. He manages all aspects of finance and helped oversee the 2011 business combination with Elan Drug Technologies (EDT). He has been the Chief Financial Officer, Vice President, Treasurer and Assistant ...

Read Full Background

Corporate Headquarters*

Connaught House
Dublin, Co. Dublin 4

Ireland

Phone: 353 1 772 8000
Fax: --

Board Members Memberships*

Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer
1998-N/A
Former Chief Financial Officer - Alkermes Development Corporation II - General Partner, Principal Accounting Officer - Alkermes Development Corporation II - General Partner, Vice President- Alkermes Development Corporation II - General Partner, Treasurer- Alkermes Development Corporation II - General Partner, Assistant Secretary - Alkermes Development Corporation II - General Partner and Director - Alkermes Development Corporation II - General Partner
2014-Present
Director, Member of Compensation Committee and Member of Audit Committee

Education*

MBA 1996
Harvard University
BA
Harvard College

Other Affiliations*

Annual Compensation*

Salary$444,066
Total Annual Compensation$444,066

Stock Options*

Restricted Stock Awards$248,250
All Other Compensation$12,875
Exercised Options174,004
Exercised Options Value$3,560,639
Exercisable Options590,746
Exercisable Options Value$16,040,617
Unexercisable Options225,125
Unexercisable Options Value$4,293,015
Total Value of Options$23,894,270
Total Number of Options989,875

Total Compensation*

Total Annual Cash Compensation$776,941
Total Short Term Compensation$444,066
Other Long Term Compensation$261,125
Total Calculated Compensation$1,831,191
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €33.96 EUR +0.175

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jean-Jacques Bienaimé Chief Executive Officer and Director
BioMarin Pharmaceutical Inc.
$868.8K
David M. Stack Chairman, Chief Executive Officer and President
Pacira Pharmaceuticals, Inc.
$916.2K
Carolyn J. Logan Chief Executive Officer, President and Director
Salix Pharmaceuticals Ltd.
$867.5K
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$771.2K
Alessandro E. Della Chà LL.MChief Executive Officer and Director
Cosmo Pharmaceuticals S.p.A.
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.